You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 8, 2025

Litigation Details for Cutting Edge Vision, LLC v. T-Mobile US, Inc. (W.D. Tex. 2024)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Cutting Edge Vision, LLC v. T-Mobile US, Inc.
The small molecule drugs covered by the patents cited in this case are ⤷  Try for Free , ⤷  Try for Free , and ⤷  Try for Free .
Biologic Drugs cited in Cutting Edge Vision, LLC v. T-Mobile US, Inc.

Litigation summary and analysis for: Cutting Edge Vision, LLC v. T-Mobile US, Inc. (W.D. Tex. 2024)

Based on the available information, here is a summary and analysis of the Cutting Edge Vision, LLC v. T-Mobile US, Inc. litigation (Case No. 6:24-cv-00270):

Key Details:

  • Filed on May 20, 2024 in the U.S. District Court for the Western District of Texas
  • Plaintiff: Cutting Edge Vision, LLC
  • Defendants: T-Mobile US, Inc. and at least one other unnamed defendant
  • Nature of Suit: Patent infringement (830 Property Rights - Patent)
  • Judge: Alia Moses
  • Referred to Magistrate Judge: Derek T. Gilliland

Summary: This appears to be a patent infringement lawsuit filed by Cutting Edge Vision against T-Mobile and at least one other defendant. The case was filed in the Western District of Texas, which is a popular venue for patent litigation.

While details are limited at this early stage, some key points and analysis:

  1. Cutting Edge Vision seems to be a patent assertion entity, as they have filed multiple similar patent lawsuits against technology companies in recent years. Their previous cases have involved patents related to mobile device displays and imaging technology.

  2. T-Mobile is likely being accused of infringing one or more patents owned by Cutting Edge Vision, potentially related to technology used in mobile devices or networks.

  3. The Western District of Texas is known for having patent-friendly local rules and faster time to trial, which may be why the plaintiff chose this venue.

  4. As a major wireless carrier, T-Mobile is frequently targeted in patent litigation. They will likely mount a vigorous defense, potentially challenging the validity of the asserted patents.

  5. At this early stage, there are no substantive rulings or claim construction orders. The case will likely proceed through initial disclosures, claim construction, and discovery over the coming months.

  6. Given the technical nature of mobile telecommunications patents, expert witnesses will likely play a key role as the case develops.

  7. Many patent cases settle before trial, so there is a possibility of early resolution if the parties can reach an agreement on licensing or other terms.

  8. If the case proceeds, a trial would likely be at least 18-24 months away based on typical timelines in this district.

This case is in its very early stages, so many details about the specific patent claims and infringement allegations are not yet available. As the litigation progresses, more information will become public through court filings. The technology and patents at issue will become clearer once the complaint is available and claim construction begins.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.